MARINOL Drug Patent Profile

« Back to Dashboard

Which patents cover Marinol, and when can generic versions of Marinol launch?

Marinol is a drug marketed by Alkem Labs Ltd and is included in one NDA.

The generic ingredient in MARINOL is dronabinol. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the dronabinol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Marinol

A generic version of MARINOL was approved as dronabinol by ASCENT PHARMS INC on February 7^th, 2020.

Summary for MARINOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	59
Patent Applications:	5,011
Drug Prices:	Drug price information for MARINOL
What excipients (inactive ingredients) are in MARINOL?	MARINOL excipients list
DailyMed Link:	MARINOL at DailyMed

See drug prices for MARINOL

Recent Clinical Trials for MARINOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Baylor College of Medicine	PHASE2
Christopher D. Verrico	PHASE2
Ralph H. Johnson VA Medical Center	Phase 2

See all MARINOL clinical trials

Pharmacology for MARINOL

Drug Class

Cannabinoid

US Patents and Regulatory Information for MARINOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-001	May 31, 1985	AB	RX	Yes	No
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-002	May 31, 1985	AB	RX	Yes	Yes
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-003	May 31, 1985	AB	RX	Yes	No

Expired US Patents for MARINOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-001	May 31, 1985
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-003	May 31, 1985
Alkem Labs Ltd	MARINOL	dronabinol	CAPSULE;ORAL	018651-002	May 31, 1985

Last updated: September 30, 2026

Marinol (dronabinol) is a mature, generic-exposed pharmaceutical with limited standalone financial disclosure and declining strategic importance relative to AbbVie’s core portfolio. Its commercial base remains concentrated in chemotherapy-related nausea and AIDS-related anorexia, while generic dronabinol, alternative cannabinoid products, and broader medical-cannabis access constrain pricing. The principal investment question is cash-flow durability, not patent-driven growth.

Marinol Market Dynamics, Patent Status, Competitive Landscape, and Financial Trajectory

What is Marinol and how is it used?

Marinol is the brand name for dronabinol, a synthetic form of delta-9-tetrahydrocannabinol, or THC. It is approved in the United States for two indications:

1. Treatment of anorexia associated with weight loss in patients with AIDS.
2. Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.[1]

Marinol is supplied as oral capsules in 2.5 mg, 5 mg, and 10 mg strengths. The product is absorbed systemically and has central nervous system effects, including dizziness, euphoria, somnolence, confusion, and impaired judgment.[1]

Dronabinol is a Schedule III controlled substance when marketed as Marinol capsules. This classification differs from some other THC-containing products and affects prescribing, distribution, and abuse-control requirements.[2]

FDA regulatory history

Milestone	Date	Significance
Initial Marinol approval	1985	Approved for chemotherapy-induced nausea and vomiting
AIDS-related anorexia indication	1992	Expanded use into appetite stimulation and weight-loss treatment
Generic dronabinol capsules	Beginning in the 1990s	Established broad multisource competition
Current FDA-approved capsule strengths	2.5 mg, 5 mg, 10 mg	Maintained across brand and generic products

Marinol was one of the first FDA-approved cannabinoid medicines. Its clinical role predates modern serotonin antagonists, neurokinin-1 antagonists, and contemporary supportive-care regimens used in oncology.

Who owns Marinol and which companies market dronabinol?

Marinol has changed ownership several times. Solvay Pharmaceuticals acquired the product before Abbott Laboratories acquired Solvay in 2010. AbbVie later became an independent company in 2013 and retained Marinol within its portfolio.[3]

The brand is associated with AbbVie, while generic dronabinol capsules have been marketed by multiple manufacturers, including major generic-drug companies and specialty suppliers. The competitive market has included products approved through abbreviated new drug applications rather than novel-drug development programs.

The commercial distinction is important:

• AbbVie controls the Marinol brand.
• Generic manufacturers compete primarily on price and availability.
• Pharmacies and payers often substitute generic dronabinol for Marinol.
• Brand retention depends on physician familiarity, patient preference, formulary rules, supply reliability, and reimbursement.

What patents protect Marinol?

Marinol has no meaningful remaining composition-of-matter patent protection. The core dronabinol molecule and the original capsule formulation were developed decades ago, and any major patent exclusivity associated with the original product has expired.

The historically relevant patent estate included patents covering synthetic THC and pharmaceutical formulations. The most commercially significant protection is no longer active in the United States.

Protection category	Current commercial relevance
Dronabinol composition	Expired
Original Marinol capsule formulation	Expired
Original therapeutic-use patents	Expired or commercially immaterial
Brand trademark	May remain enforceable, but does not block generic entry
Manufacturing know-how	Potentially useful operationally, but not a major market barrier
New delivery-system patents	Relevant only if tied to a distinct later product

The FDA Orange Book is the principal source for approved drug products, therapeutic-equivalence information, and listed patents. Marinol’s competitive position is not based on an active patent wall comparable to newer specialty medicines.[4]

What formulations are protected by Marinol patents?

The original Marinol dosage form is an oral capsule containing dronabinol in sesame oil. Its formulation is technically distinct from later oral solutions and nonoral cannabinoid products, but that distinction does not create durable commercial exclusivity by itself.

Formulation-related protections can matter when they cover:

• Improved dissolution or absorption.
• Reduced variability in exposure.
• A non-oil delivery system.
• A liquid product suitable for patients who cannot swallow capsules.
• A formulation with reduced food-effect variability.
• A controlled-release or mucosal delivery system.

Marinol does not retain a current formulation barrier that prevents generic capsule competition. Generic manufacturers can enter through FDA approval pathways if they demonstrate pharmaceutical equivalence and bioequivalence.

When did Marinol lose exclusivity?

Marinol lost practical market exclusivity years ago. Generic dronabinol capsules entered the U.S. market after the expiration of early Marinol-related protections, leaving the brand exposed to substitution and reimbursement pressure.

No current patent-based exclusivity period protects Marinol from generic dronabinol capsules. Any remaining brand value comes from product recognition, prescribing history, commercial distribution, and patient or physician preference rather than exclusivity.

Is Marinol subject to Paragraph IV challenges?

Paragraph IV litigation is not a material current risk driver for Marinol because generic dronabinol products have already entered the market. Paragraph IV certifications are most important before first generic entry, when a challenger alleges that listed patents are invalid, unenforceable, or not infringed.

For Marinol, the relevant commercial event is historical generic entry, not a pending first-wave Paragraph IV contest. Later generic manufacturers may rely on existing regulatory pathways and may not need to create a new market-opening litigation event.

What is the Orange Book status of Marinol?

Marinol is an FDA-approved prescription drug listed in FDA drug-product records. The Orange Book provides the relevant reference-product and therapeutic-equivalence framework for generic dronabinol capsules.[4]

The current commercial interpretation is:

• Marinol is the reference brand.
• Generic dronabinol capsules are available.
• Brand and generic products compete within the same oral capsule category.
• Patent listings do not provide a current barrier to ordinary generic substitution.
• Product-specific regulatory requirements remain relevant even after patent expiration.

FDA approval does not guarantee reimbursement or brand retention. Payer formularies often prefer generic dronabinol unless clinical, supply, or administrative factors support Marinol coverage.

How large is the Marinol market?

Public companies do not generally disclose Marinol sales as a separate line item. AbbVie reports revenue by major therapeutic area and selected products, but Marinol is not treated as a major individually reported franchise in the company’s public financial reporting.[5]

This limits precise estimates of:

• Annual Marinol brand revenue.
• Gross-to-net deductions.
• U.S. versus international revenue.
• Brand versus generic market share.
• Product-level operating margin.

The market is best characterized as a mature specialty and legacy product category. Its value is supported by recurring prescriptions but constrained by:

1. Generic competition.
2. Low growth in the underlying indications.
3. Availability of alternative antiemetic regimens.
4. Expansion of regulated cannabis products in some jurisdictions.
5. Limited investment in brand promotion.
6. Product stigma and tolerability concerns.
7. Schedule-related distribution controls.

Revenue exposure for AbbVie

Marinol is unlikely to be financially material to AbbVie on a consolidated basis. AbbVie’s major revenue drivers include immunology, oncology, neuroscience, aesthetics, and other specialty products. Marinol is a legacy asset relative to larger products such as Skyrizi, Rinvoq, Botox, and Vraylar.[5]

The product can still contribute positive cash flow if manufacturing and commercial costs are low. Its financial profile is likely closer to a maintenance product than a growth asset.

Financial factor	Marinol impact
Revenue growth	Low to negative under generic pressure
Pricing power	Weak
Gross margin	Potentially attractive if production costs are low
Sales expense	Likely limited relative to strategic brands
Patent expiry risk	Already realized
Generic substitution	High
Strategic value	Portfolio continuity and residual cash generation
Valuation relevance	Limited at AbbVie group level

What are the main market dynamics affecting Marinol?

Generic dronabinol pressure

Generic substitution is the largest structural constraint. Once multiple approved manufacturers supply dronabinol capsules, the brand must compete against lower acquisition costs and payer preferences.

Generic pressure affects Marinol through:

• Lower net price.
• Reduced pharmacy stocking incentives.
• Formulary exclusion or higher patient copayments.
• Lower physician motivation to specify the brand.
• Greater sensitivity to supply disruptions.

Competition from modern antiemetics

For chemotherapy-induced nausea and vomiting, Marinol competes with therapies that are often used earlier in treatment protocols. These include serotonin receptor antagonists, NK1 receptor antagonists, dexamethasone-based regimens, and olanzapine-containing protocols.[6]

Dronabinol may be used when standard treatments are inadequate or poorly tolerated. That creates a narrower role than its original regulatory positioning suggests.

Competition from cannabis products

State-regulated medical and adult-use cannabis markets create indirect competition, although cannabis products are not interchangeable with FDA-approved Marinol. Differences include:

• Variable cannabinoid content.
• Different manufacturing standards.
• Nonuniform clinical evidence.
• Distinct legal status.
• Different reimbursement treatment.
• Different routes of administration.

Cannabis access can reduce demand among some patients seeking appetite stimulation or symptom relief. It also can increase public familiarity with cannabinoid therapy, which may support broader interest in prescription products. The net effect is indication- and market-specific.

AIDS-related anorexia

The AIDS-related appetite-stimulation market is smaller than when Marinol was approved. Antiretroviral therapy has improved disease control and reduced the prevalence of severe wasting in treated populations. This limits long-term volume growth for the original anorexia indication.

Marinol remains clinically relevant for selected patients, but the addressable population is narrower than in the early 1990s.

How does Marinol compare with Syndros and generic dronabinol?

Syndros is an FDA-approved oral solution containing dronabinol. It provides a liquid administration option and has different controlled-substance scheduling from Marinol capsules under federal law.[7]

Attribute	Marinol	Generic dronabinol capsules	Syndros
Active ingredient	Dronabinol	Dronabinol	Dronabinol
Dosage form	Oral capsule	Oral capsule	Oral solution
Key differentiation	Established brand	Lower-cost substitution	Liquid delivery
Patent-driven protection	No material current barrier	N/A as generic products	Product-specific protection may differ
Patient fit	Patients able to swallow capsules	Same general use	Patients needing liquid dosing
Pricing position	Brand-exposed	Generally lower	Specialty formulation positioning
Competitive risk	High generic substitution	Price competition	Alternative dosage form

Syndros illustrates the commercial value of formulation differentiation. A liquid dosage form can target patients who have swallowing difficulties or require more flexible titration. It does not automatically displace the capsule market because reimbursement, prescribing habits, and pricing remain important.

What patent litigation and settlement agreements affect Marinol?

No major current patent litigation is central to the Marinol market. The product’s principal patent disputes occurred during the earlier generic-entry period, when generic manufacturers sought approval despite listed patents or after relevant protections had expired.

There is no current litigation-based exclusivity event comparable to a first generic challenge against a recently launched specialty medicine. Settlement agreements, if any, do not appear to be a material driver of present-day Marinol revenue.

The relevant legal risks now involve:

• Product liability.
• Controlled-substance compliance.
• Manufacturing and quality systems.
• Labeling and promotional compliance.
• Generic substitution and reimbursement disputes.
• Supply continuity.

What generic launch scenarios exist for Marinol?

Generic launch risk is already realized, but further erosion can occur under several scenarios.

Continued multisource erosion

Additional generic suppliers can reduce prices and increase pharmacy substitution. This is the most likely baseline scenario.

Generic consolidation

If manufacturers exit because of low margins, supply may consolidate. Consolidation could temporarily support pricing or create shortages, but it would not restore patent exclusivity.

Brand retention in narrow segments

Marinol may retain use where physicians prefer the branded product, patients report better tolerability, or pharmacies face generic supply constraints. This supports residual revenue but does not create a growth trajectory.

Formulation migration

Patients who require liquid dosing may shift toward Syndros or compounded alternatives, while capsule users remain in the Marinol-generic market.

How strong is the Marinol patent estate?

Marinol has a weak current patent estate from a market-defense perspective. Its strengths are historical and operational rather than exclusivity-based.

Patent-estate criterion	Assessment
Core molecule protection	Expired
Active U.S. composition patent	No material protection
Active capsule formulation barrier	No material barrier to generic capsules
Method-of-use protection	No meaningful current commercial moat
Manufacturing complexity	Moderate but manageable
Regulatory switching barrier	Low to moderate
Brand recognition	Moderate
Overall defensive strength	Weak

The remaining barriers are practical: controlled-substance handling, quality manufacturing, product consistency, and distribution. These barriers can slow entry or affect supply, but they do not prevent generic competition.

What is Marinol’s likely financial trajectory?

Marinol’s likely trajectory is flat to declining revenue with residual profitability. The product has limited ability to increase price, expand indications, or defend share through patents.

Base case

Generic substitution continues, and brand revenue declines gradually. AbbVie retains the product while operating costs remain controlled.

Downside case

More generic suppliers, lower reimbursement, and reduced demand in AIDS-related anorexia accelerate brand erosion. The product becomes commercially immaterial even if it remains available.

Upside case

Supply disruptions among generic manufacturers, renewed interest in pharmaceutical cannabinoids, or improved positioning in refractory chemotherapy-related nausea stabilizes demand. This upside is unlikely to produce material growth without a differentiated formulation or new clinical evidence.

Marinol’s value is therefore primarily cash-flow based. A buyer would focus on manufacturing cost, net pricing, supply reliability, controlled-substance compliance, and the durability of the residual patient base rather than on patent life.

Key Takeaways

• Marinol is the branded oral capsule formulation of dronabinol.
• FDA approvals cover chemotherapy-induced nausea and vomiting and AIDS-related anorexia associated with weight loss.
• The product has no meaningful remaining U.S. patent exclusivity.
• Generic dronabinol capsules are the principal competitive threat and have already established market access.
• AbbVie does not separately disclose Marinol revenue in a way that supports precise product-level financial modeling.
• The AIDS-related anorexia market is structurally smaller than at the time of initial approval.
• Modern antiemetics limit Marinol’s role in oncology.
• Cannabis products create indirect competition but are not FDA-equivalent substitutes.
• Syndros competes through a liquid dronabinol formulation.
• Marinol is best modeled as a mature, low-growth or declining legacy asset with potential residual cash flow.

FAQs About Marinol Market Dynamics and Exclusivity

Does Marinol still have patent protection?

No material patent protection remains that prevents generic dronabinol capsule competition in the United States. The original molecule and core product protections are long expired.

Is Marinol interchangeable with generic dronabinol?

FDA-approved generic dronabinol capsules may be therapeutically equivalent to the reference product when listed as such in the Orange Book. Pharmacy substitution depends on state law, payer policy, and product-specific FDA determinations.[4]

Is Marinol covered by Medicare?

Coverage depends on the Medicare plan, indication, formulary tier, prior authorization rules, and whether the product is obtained through a covered prescription benefit. Generic dronabinol typically has stronger formulary positioning than the branded product.

Is Marinol safer than medical cannabis?

Marinol has standardized strength, FDA-reviewed labeling, and pharmaceutical manufacturing controls. Medical cannabis products vary by jurisdiction, formulation, cannabinoid content, and quality controls. Safety cannot be assessed solely by brand or product category.

Can a company create new exclusivity around dronabinol?

A company could pursue exclusivity for a genuinely differentiated formulation, delivery system, manufacturing process, or new approved indication. Any protection would need to satisfy FDA regulatory requirements and applicable patentability standards. It would not restore exclusivity to the original Marinol capsule automatically.

References

1. U.S. Food and Drug Administration. (2023). Marinol (dronabinol) capsules prescribing information. FDA.

2. U.S. Drug Enforcement Administration. (2024). Drug scheduling. U.S. Department of Justice.

3. AbbVie Inc. (2013). Form 10-K for the fiscal year ended December 31, 2012. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. AbbVie Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.

6. National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Antiemesis. NCCN.

7. U.S. Food and Drug Administration. (2023). Syndros (dronabinol) oral solution prescribing information. FDA.